-1.png&w=3840&q=75)
Is recurrent implantation failure a distinct clinical entity — or a statistical artefact created by the absence of a unified definition? Data on cumulative pregnancy and live birth rates across serial euploid embryo transfers, plus consensus algorithms (ESHRE 2023, Lugano 2023) for diagnosis, work-up and management.
Audio: ENUARUSubtitles: ENUARU31 min
Luteal phase support based on serum progesterone monitoring: why standard vaginal therapy fails to reach the protective level in a subset of patients on the hormone replacement cycle, how to define the threshold value on transfer day, and when a change in the route of administration is indicated. Arguments for moving toward natural and modified natural FET cycles.
Audio: ENUARUSubtitles: ENUARU27 min
The impact of overweight and obesity on reproductive outcomes: ovarian response, embryo quality, endometrial receptivity and obstetric consequences. Why BMI alone is insufficient for clinical decisions — and how body composition assessment (bioelectrical impedance, indirect calorimetry, food diary) makes pre-cycle workup truly individualized.
Audio: ENUARUSubtitles: ENUARU32 min
Adenomyosis and infertility: phenotype classification (internal/junctional zone, intermediate, external), current diagnostic approaches (MRI, ultrasound per MUSA criteria, hysteroscopy) and the evidence base regarding impact on ART outcomes. Management algorithm in clinically significant adenomyosis: cycle segmentation, accumulation of euploid blastocysts, GnRH agonist pretreatment before FET, selective hysteroscopic resection.
Audio: ENUARUSubtitles: ENUARU33 min
Thin endometrium remains one of the most debated topics in reproductive medicine. Is it justified to cancel transfer at a thickness of <7 mm? Analysis of the evidence base — from classical work of the late 1980s to current multicentre cohorts (~30,000 cycles) — shows that with proper work-up (exclusion of intracavitary pathology and premature progesterone exposure), the live birth rate at thickness <7 mm remains in the 42–47% range.
Audio: ENUARUSubtitles: ENUARU28 min
Why does luteal progesterone matter just as much in fresh cycles as in frozen? A walk-through of trigger choice, mid-luteal cut-offs and rescue strategies for the suboptimal corpus luteum — built on more than 15 years of randomised trials.
Audio: ENUARUSubtitles: ENUARU36 min
HRT, modified natural or true natural cycle — which preparation actually delivers the best obstetric outcomes? A practical synthesis of recent data on E2 duration, progesterone route and timing, day-of-transfer monitoring, and the new NPP protocol that may reshape weekend scheduling.
Audio: ENUARUSubtitles: ENUARU37 min
Receptive or non-receptive? A continuum-based view of the endometrium as an active biosensor that selects against poor-quality embryos. Why the classical 'all in the egg' narrative misses recurrent implantation failure — and how a new diagnostic toolbox is taking shape.
Audio: ENUARUSubtitles: ENUARU39 min
Lactobacillus dominance, the ENMA test, and a personalised antibiotic-probiotic pathway: how far has the evidence for the endometrial microbiome come in IVF? Live-birth data, host-microbial interactions at the GPCR level, and what to do with a dysbiotic sample before transfer.
Audio: ENUARUSubtitles: ENUARU36 min
How much of IVF failure happens after the transfer catheter leaves the cervix? An unpublished preview of next-generation embryo transfer — robotic microfluidic injection into a defined endometrial pocket under image guidance, on the way to first-in-human trials.
Audio: ENUARUSubtitles: ENUARU21 min
From at-home hormonal screening and ultrasound classifiers to CD138 detection in chronic endometritis and endometrium-on-chip — a tour of where artificial intelligence already adds value across the IVF cycle, and where its real limits sit today.
Audio: ENUARUSubtitles: ENUARU29 min
Are antral follicles really gonadotrophin-dependent only at one stage — or all the way through? A walk through the LH receptor, the two-cell two-gonadotrophin model and what the 2023 reframing of folliculogenesis means for choosing a stimulation protocol.
Audio: UASubtitles: ENUARU26 min
Why does one patient respond to FSH alone while another stalls without LH? Polymorphisms of FSHR, LHCGR and ESR — what genetic markers explain stimulation failures, and where genotyping starts paying off in routine practice.
Audio: UASubtitles: ENUARU18 min
PCOS affects 8-13% of women of reproductive age and drives 70% of anovulatory infertility. A look at the role of elevated LH in PCOS pathogenesis, the 2023 international guideline, the revised Rotterdam criteria — and what a personalised stimulation pathway looks like in 2026.
Audio: UASubtitles: ENUARU27 min
An 18-oocyte cycle at 40 with a poor maturation rate is no longer surprising. Why advanced reproductive age is not only quantity but quality, what relative LH deficiency does to oocyte competence, and how to read the LH:FSH ratio when planning a stimulation in the over-38 patient.
Audio: UASubtitles: ENUARU29 min
A 35-year-old with normal AMH, normal FSH/LH and 4 years of unexplained infertility. Triple trigger, 19 oocytes retrieved — and 79% immaturity. The talk uses real cases to walk through random-start, DuoStim and the role of LH supplementation when standard stimulation hits a wall.
Audio: UASubtitles: ENUARU25 min
The trigger is one small injection at the end of stimulation — and most of the cycle outcome rides on it. A practical walk through trigger choice (HCG, agonist, dual, double), the Vienna consensus 80-95% oocyte yield ratio, and what each trigger does to oocyte maturation in real protocols.
Audio: UASubtitles: ENUARU50 min
Three buckets of patients: those where LH is non-negotiable, those where it almost is, and those where you can manage without. The talk classifies clinical scenarios — hypogonadotrophic hypogonadism, LH receptor polymorphisms, advanced reproductive age — and gives a decision tree for when recombinant LH actually changes the cycle outcome.
Audio: UASubtitles: ENUARU37 min
Why does the corpus luteum still matter when we transfer in HRT? A walk through 40+ years of LH-progesterone evidence, three studies (two fundamental, one practical) on luteal-phase support, and where the 22+ existing FET protocols separate into corpus-luteum-supported and corpus-luteum-free strategies.
Audio: UASubtitles: ENUARU32 min
We can save money anywhere in an IVF cycle — the real question is what we pay for that. A frank look at the cost structure of stimulation, the low-cost-airline analogy, NHSU reimbursement realities and how to find a defensible balance between price and result without compromising live-birth rate.
Audio: UASubtitles: ENUARU27 min
Lecture by Nataliia Vladykina, Medical Director of LITA clinic, reproductive medicine specialist and geneticist (Kyiv), on pharmacogenomics in ovarian stimulation. Why patients with a normal AMH and antral follicle count give a sub-optimal response and how to predict it: FSH receptor polymorphisms (Asn680Ser, position 307), the FOI index, the POSEIDON 1-2 classification, the Alviggi/Conforti Delphi consensus, FSH+LH receptor synergy from GenOx 2025, ethnic differences, Belen Lledó's AI prediction model and the rationale for urinary FSH in Ser-Ser carriers.
Audio: UASubtitles: ENUARU23 min
An expanded lecture by Vitalii Radko, MD PhD, Head of Department at Mother and Child Medical Centre (Kyiv), on applying pharmacogenomics beyond FSH/LH receptors — in complex ART clinical cases. The 180-gene infertility panel, ESR1/ESR2 polymorphisms in oocyte donors (Belen Lledó, Bernabeu Institute), the ESR2 rs4986938 marker for idiopathic thin endometrium, poor blastulation in patients under 40 and calcium ionophore in a selected cohort, the WEE2 gene — recurrent ICSI fertilisation failures, true empty follicle syndrome via LHCGR and zona pellucida proteins ZP1-3.
Audio: UASubtitles: ENUARU36 min
What can two extreme clinical scenarios — hypogonadotropic hypogonadism and polycystic ovarian morphology — teach us about LH in early folliculogenesis? Reading the boundary cases is often how the central mechanism becomes visible.
Audio: ENUARUSubtitles: ENRUUA34 min
Why do two patients with the same age, AMH and antral count respond differently to the same stimulation? A look at the genetic markers — FSHR, LHCGR, ESR polymorphisms — that increasingly drive personalised protocol design.
Audio: ENUARUSubtitles: ENRUUA34 min
More oocytes is not the same as more euploid embryos. A focused look at whether adding recombinant LH to FSH shifts not only the yield, but the proportion of euploid blastocysts — drawing on Meseguer's own data.
Audio: ENUARUSubtitles: ENRUUA29 min
Hypo-response often gets blamed on the patient — but maybe the protocol picked the fight on the wrong day. Can up-front optimisation of stimulation, LH supplementation and trigger choice prevent a hypo-response cycle from the very first day?
Audio: ENUARUSubtitles: ENRUUA25 min
POSEIDON groups 1-4 reshaped how we think about poor ovarian response. Almost a decade on, what has the framework gained, where has it been pressure-tested by clinical reality, and how does it map to live-birth outcomes today?
Audio: ENUARUSubtitles: ENRUUA42 min
Behind every semen analysis lies a testicle, and behind every testicle lies endocrine regulation. APHRODITE — published in Reproductive Biomedicine Online 2024 — stratifies male infertility into five endocrine phenotypes and asks who actually benefits from gonadotropin therapy, and who does not.
Audio: ENUARUSubtitles: ENRUUA42 min
Stimulation begins with physiology. How gonadotropin-dependent and -independent stages of follicle growth, the FSH window and intra-ovarian factors determine why some protocols work and others do not — and how to read this at the individual patient.
Audio: UA34 min
Master the fundamentals before adding complexity. Agonist and antagonist protocols, choice of gonadotropins and starting dose, individualisation to ovarian reserve — the systematic toolkit every stimulation programme starts from.
Audio: UA30 min
The stimulation paradigm has shifted from 'more oocytes at any cost' to personalisation and safety. Which factors really drive protocol choice today, how freeze-all and cycle segmentation changed decision logic, and where the limits of reasonable individualisation lie.
Audio: UA27 min
The classic 'day 2–3' start is no longer the only option. When it is appropriate to start stimulation regardless of cycle phase, how dual stimulation (DuoStim) raises the cumulative oocyte yield in challenging patients, and where the limits of these approaches lie.
Audio: UA19 min
Most stimulation complications are predictable. How to assess the risk of ovarian hyperstimulation syndrome, when an agonist trigger and freeze-all are the rescue, how to choose the final maturation trigger, and which mistakes cost a cycle — a practical review of prevention.
Audio: UA30 min
Natural, modified natural or hormone replacement cycle — what determines the choice? A comparison of endometrial preparation protocols for frozen embryo transfer, the role and monitoring of progesterone, and synchronising the implantation window with embryo transfer.
Audio: UA18 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU25 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU34 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU29 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU24 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU34 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU34 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU29 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU24 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU18 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU41 min
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU16 min
Targeted, biomarker-guided immunotropic therapy in reproductive medicine. A lecture by Kseniia Khazhylenko at the UARM Symposium 2026.
Audio: UASubtitles: UA32 min
A practical UARM 2026 masterclass on controlled ovarian stimulation, complication prevention and endometrial preparation for frozen embryo transfer. Six lectures and two discussions from leading Ukrainian reproductologists.
Audio: UA3h 18m
International scientific symposium organised by Sona-Pharm and Sona Academy at the Summer School of Reproductologist in London, 8 July 2026. Hybrid format — in person at Holiday Inn London – Bloomsbury or online via live stream. Six precision-focused lectures on LH biology, genetics of ovarian response, protocol optimisation, POSEIDON and APHRODITE — with a discussion after each block.
Audio: ENUARUSubtitles: ENRUUA4h 57m
Forum of the Association of Diabetologists, 19–20 March 2026, Almaty, Kazakhstan.
Audio: ENUARUSubtitles: ENUARU1h 15m
Sona-Pharm webinar for IVF specialists, 10 September 2025. Speaker: Professor Peter Humaidan.
Audio: ENUARUSubtitles: ENUARU53 min
Vivere et Discere is a discussion club for reproductive medicine specialists by Sona-Pharm and Sona Academy, built around live debate driven by questions from the audience and chat. Edition of 15 April 2026: pharmacogenomics in ART, two lectures + full discussion with Nataliia Vladykina (LITA) and Vitalii Radko (Mother and Child MC).
Audio: UASubtitles: ENUARU1h 51m
Recorded lectures from Winter School of Reproductologist 2026: LH as the Key to ART Success. Nine expert lectures and two live Q&A sessions covering LH physiology, FSH/LH receptor polymorphisms, PCOS, random-start protocols, trigger selection, and pharmacoeconomics. Speakers from IVMED, LITA, Medical Plaza, REPROLIFE, «Mother and Child» MC, and YUZKO MC.
Audio: UASubtitles: ENUARU6h 5m
Recorded lectures from the 2024 Summer School for Reproductologist — international faculty on endometrial preparation for fresh and frozen transfers, receptivity testing, the endometrial microbiome, automated embryo transfer and AI in IVF.
Audio: ENUARUSubtitles: ENUARU4h 9m
Recorded lectures from the 2025 Summer School for Reproductologist — international faculty on implantation failure, luteal phase support, obesity, adenomyosis and thin endometrium.
Audio: ENUARUSubtitles: ENUARU3h 15m
Two lectures. Two frameworks. One question at the center: are we making gonadotropin decisions based on biology — or on habit? LH supplementation in women and endocrine phenotyping in men are not new topics. But the evidence base has shifted, and so have the tools available to clinicians. POSEIDON has changed how we think about poor ovarian response. APHRODITE is now changing how we classify male infertility. Both frameworks were presented here by the researchers who created them. This course captures that conversation — not as theory, but as a clinical argument for moving from empirical to phenotype-based decision-making.
Audio: ENUARUSubtitles: ENUARU1h 8m
A seven-module masterclass on glaucoma management by Volodymyr Melnyk, MD, PhD — Founder and Medical Director of VISIOBUD Clinic, Head of the NGO Union of Ukrainian Ophthalmic Surgeons, and Member of the ESCRS Glaucoma Committee. From definition, hydrodynamics and pathogenesis to diagnostic strategy, medical treatment, classical surgery, MIGS and clinical cases — built around the author's own surgical techniques and a practice of around 3,000 eye operations a year.
Audio: UASubtitles: ENUARU5h 31m
Summer School of Reproductologist 2023 in Cannes: 11 lectures by leading international experts on ovarian physiology, ovarian stimulation, management of poor-prognosis patients and assessment of oocytes and embryos.
Audio: UARUSubtitles: UARU5h 50m
Is the LH you measure the same as the LH the follicle actually receives? Serum levels do not capture bioactivity or receptor function — and yet most stimulation decisions are made on a single number. A look at three patient groups where LH supplementation moves the cycle: congenital deficiency, antagonist-induced suppression and the over-35 ovarian profile.
Audio: ENUARUSubtitles: ENUARU41 min
Behind every semen analysis lies a testicle, and behind every testicle lies endocrine regulation. The APHRODITE framework — published in Reproductive Biomedicine Online 2024 — stratifies male infertility into five endocrine phenotypes based on FSH, testosterone and semen, and asks a sharper question: who actually benefits from gonadotropin therapy, and who does not?
Audio: ENUARUSubtitles: ENUARU27 min
The failed implantation of a euploid blastocyst is a clinical problem that bridges two schools of thought: «embryo-centric» and «endometrium-centric». The concept of the endometrium as a biosensor explains why, with embryos of average quality, endometrial receptivity and selectivity determine the outcome. A review of current evidence and the clinical grading of RIF (recurrent implantation failure) per the ESHRE 2023 consensus.
Audio: ENUARUSubtitles: ENUARU40 min